Gilead Sciences (GILD) Misses Q4 EPS by 37c, Offers Guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
EPS Growth %: -462.7%
Financial Fact:
Interest expense: -242M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.30, $0.37 worse than the analyst estimate of $1.67. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.71 billion.
GUIDANCE:
Gilead Sciences sees FY2020 EPS of $6.05-$6.45, versus the consensus of $7.01.
Product Sales |
| $21,800 - $22,200 |
Non-GAAP |
|
|
Product Gross Margin |
| 86% - 87% |
R&D Expenses |
| Mid-single digit percentage growth |
SG&A Expenses |
| Mid-single digit percentage growth |
Operating Income |
| $10,100 - $10,800 |
Effective Tax Rate |
| ~ 21% |
Diluted EPS |
| $6.05 - $6.45 |
GAAP Diluted EPS |
| $5.15 - $5.55 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- After-Hours Stock Movers: FDX, CBRS, NKE
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
